- Home
- EXAS vs BHFAN Comparison
EXAS vs BHFAN Comparison
Compare EXAS & BHFAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EXAS | BHFAN |
|---|---|---|
| Founded | 1995 | N/A |
| Country | United States | United States |
| Employees | N/A | 1400 |
| Industry | Medical Specialities | Life Insurance |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EXAS | BHFAN |
|---|---|---|
| Price | $101.58 | $12.50 |
| Analyst Decision | Buy | |
| Analyst Count | 20 | 0 |
| Target Price | ★ $77.94 | N/A |
| AVG Volume (30 Days) | ★ 10.8M | N/A |
| Earning Date | 11-03-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,082,033,000.00 | N/A |
| Revenue This Year | $19.40 | N/A |
| Revenue Next Year | $13.51 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.47 | N/A |
| 52 Week Low | $38.81 | N/A |
| 52 Week High | $101.95 | N/A |
Technical Indicators
Market Signals| Indicator | EXAS | BHFAN |
|---|---|---|
| Relative Strength Index (RSI) | 89.65 | 36.51 |
| Support Level | $100.95 | $12.44 |
| Resistance Level | $101.95 | $13.33 |
| Average True Range (ATR) | 0.35 | 0.31 |
| MACD | -0.87 | -0.09 |
| Stochastic Oscillator | 61.17 | 4.34 |
Price Performance
Historical ComparisonAbout EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About BHFAN Brighthouse Financial Inc. Depositary shares each representing a 1/1000th interest in a share of 5.375% Non-Cumulative Preferred Stock Series C
Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are Annuities, Life, Run-off and Corporate and Other. It derives a majority of the revenue from the Annuities segment which includes variable, fixed, index-linked, and income annuities. The life segment includes variable, term, universal, and whole life policies.